产品名称：Seribantumab
中文名称：瑟瑞妥单抗
产品别称：MM121, SAR256212
靶点：HER3 [Homo sapiens]
抗体亚型：IgG2 - lambda
体外实验：Seribantumab (0-0.5 μmol/L; 96 h) 强烈抑制 NRG1-b1 刺激的 MCF-7 细胞的生长[1]。
Seribantumab (0.1, 1 and 10 μmol/L; 24-48 h) 有效抑制NRG1融合或NRG1扩增的乳腺癌细胞（MDA-MB-175-VII, DOC4-NRG1）和肺癌（LUAD-0061AS3， SLC3A2-NRG1融合）癌细胞（HCC-95）的生长[1]。
体内实验：在高级别浆液性卵巢癌 (HGSOC) 小鼠模型中，Seribantumab可以消除绝大多数肿瘤细胞[1]。
| Animal Model | PDX mouse model of high-grade serous ovarian cancer (HGSOC) |
| Dosage | 1, 2.5, 5, or 10 mg seribantumab (twice weekly) |
| Result | Effectively reduced tumor growth of mice and time- and dose-dependently reduced phosphorylation of HER2, HER3, AKT, and ERK1/2. Induced the expression if proapoptotic protein, BIM. |
参考文献：1.Odintsov I, Lui AJW, Sisso WJ, et al. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. Clin Cancer Res. 2021;27(11):3154-3166. doi:10.1158/1078-0432.CCR-20-3605
仅供科研使用
